3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Tumor-Agnostic
1
Thoracic
1
NET
1
Endocrine
1
Conditions
Gastrointestinal Stromal Tumors
31
Colorectal Neoplasms
12
Pancreatic Neoplasms
11
Carcinoma, Hepatocellular
11
Stomach Neoplasms
8
Neoplasms
7
Liver Neoplasms
7
Esophageal Neoplasms
6
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Gastrointestinal Neoplasms
5
Adenoma, Islet Cell
5
Neuroendocrine Tumors
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Carcinoma
3
Thyroid Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Adenoma
2
Adenocarcinoma Of Esophagus
2
Interventions
Oxaliplatin
30
Gemcitabine
28
Fluorouracil
27
Capecitabine
22
Leucovorin
19
pembrolizumab
15
130-nm albumin-bound paclitaxel
13
Irinotecan
12
Cisplatin
11
Bevacizumab
11
Albumin-Bound Paclitaxel
11
Paclitaxel
10
Ramucirumab
8
Radiotherapy
8
Docetaxel
8
Nivolumab
7
trastuzumab deruxtecan
6
Cyclophosphamide
6
Taxes
5
Drug Therapy
5
durvalumab
4
Trastuzumab
4
Metformin
4
zolbetuximab
3
spartalizumab
3
folfirinox
3
cemiplimab
3
XELOX
3
Surgical Procedures, Operative
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Sunitinib
×
Gastrointestinal
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled